Key Highlights

• Sintx Technologies will deliver 255,267 shares from the 507,254 share abeyance without additional cash.

• The balance of 251,987 shares held in abeyance will be substituted with a pre‑funded warrant that mirrors that share count.

• An older warrant for 760,881 shares is being cancelled and replaced by a new warrant for 1,268,135 shares with an exercise price of $2.14 per share.

• Both the pre‑funded and new warrants are subject to a 9.99% beneficial ownership limit and comply with applicable Nasdaq listing rules.

Sintx Technologies, Inc. (NASDAQ: SINT) entered into a definitive Letter Agreement with MedTech Ceramics, LP in late June to address a sizeable block of shares that had been placed in abeyance following a prior warrant inducement. The agreement focuses on a total of 507,254 shares that were previously restricted from public trading.

Share Issuance Detail

Under the agreement, Sintx will promptly deliver 255,267 shares to MedTech Ceramics. No additional cash consideration is required because the prior inducement satisfied payment obligations. This action transfers the shares from abeyance into the public float, enhancing liquidity.

Pre‑Funded Warrant Substitution

The remaining 251,987 shares that remain in the abeyance pool will be substituted with a pre‑funded common stock purchase warrant. The warrant is structured to reflect the same share count and can be exercised without further cash outlay, using a cash‑less mechanism until fully exercised.

Replacement of Existing Warrant

MedTech Ceramics previously held a September warrant authorizing the purchase of 760,881 shares. That warrant is being cancelled and replaced by a new common stock purchase warrant that provides the right to acquire 1,268,135 shares at an exercise price of $2.14 per share.

New Warrant Terms

The newly issued warrant carries a multi‑year term and may be exercised either with cash or via a cash‑less method if a registration statement is unavailable after a reasonable period. The exercise price includes a full‑ratchet downward adjustment that would trigger in the event of dilutive equity financing, subject to shareholder approval as required by applicable Nasdaq listing rules.

Capital Structure Impact

Sintx indicated that these transactions are part of an ongoing effort to refine its capital structure and bolster shareholder equity. While the moves are expected to strengthen the equity position, the ultimate impact will depend on the company’s overall financial performance and operating results. The company also committed to file a resale registration statement for the shares that may be issued upon exercise of the new warrant within a statutory timeframe.

Regulatory and Anti‑Dilution Measures

Standard anti‑dilution provisions and adjustment mechanisms for stock splits, dividends, and other fundamental transactions apply to both warrants. These clauses are designed to protect existing shareholders while providing flexibility for future financing activities.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.